These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Flouroquinolone activity in clinical isolates of Streptococcus pneumoniae with different susceptibility to penicilline: an epidemiological study in five cities of Mexico].
    Author: Calva-Mercado JJ, Castillo G, López-Vidal Y.
    Journal: Gac Med Mex; 2005; 141(4):253-8. PubMed ID: 16164118.
    Abstract:
    OBJECTIVE: Determine the susceptibility to five fluoroquinolones and cross-resistance of pneumococcusclinical isolates with different penicillin susceptibilities gathered in a community-based study. DESIGN: Cross-sectional survey. MATERIALS: Two hundred and thirty one (231) isolates were obtained from respiratory secretions or blood specimens from 231 patients with acquired acute respiratory infection or bacteremia. OUTCOME MEASURES: In vitro susceptibility to penicillin (PEN), ciprofloxacin (CIP), levofloxacin (LEV), gatifioxacin (GAT), moxifloxacin (MOX) and gemifioxacin (GEM) was determined with minimal inhibitory concentration (MIC) using the E test. RESULTS: 42% of the isolates showed decreased susceptibility to PEN. The lowest antibiotic concentration that inhibited 90% of the isolates was 3 microg/ml (for CIP), 1 microg/ml (for LEV), 0.25 microg/ml (for GAT), 0.125 microg/ml (for MOX) and 0.032 microg/ml (for GEM). Median MIC for LEV, GAT, MOX and GEM increased with decreasing susceptibility to CIP. Susceptibility to CIP was similar between penicillin-susceptible and penicillin-resistant pneumococci. CONCLUSION: Third and fourth generation fluoroquinolones showed very high inhibitory activity, higher than that for CIP, for both penicillin-susceptible and penicillin-resistant pneumococci. We noted cross-resistance among fluoroquinolones.
    [Abstract] [Full Text] [Related] [New Search]